{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:06:01Z","timestamp":1792609561218,"version":"4.5.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Different prophylactic and episodic clotting factor treatments are used in the management of hemophilia. A summarize of the evidence is needed inform decision-making.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Objective<\/jats:title><jats:p>To compare the effects of factor replacement therapies in patients with hemophilia.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Methods<\/jats:title><jats:p>We performed a systematic search in PubMed, Central Cochrane Library, and Scopus. We included randomized controlled trials (RCTs) published up to December 2020, which compared different factor replacement therapies in patients with hemophilia. Random-effects meta-analyses were performed whenever possible. The certainty of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. The study protocol was registered in PROSPERO (CRD42021225857).<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Results<\/jats:title><jats:p>Nine RCTs were included in this review, of which six compared episodic with prophylactic treatment, all of them performed in patients with hemophilia A. Pooled results showed that, compared to the episodic treatment group, the annualized bleeding rate was lower in the low-dose prophylactic group (ratio of means [RM]: 0.27, 95% CI: 0.17 to 0.43), intermediate-dose prophylactic group (RM: 0.15, 95% CI: 0.07 to 0.36), and high-dose prophylactic group (RM: 0.07, 95% CI: 0.04 to 0.13). With significant difference between these subgroups (p = 0.003, I<jats:sup>2<\/jats:sup>= 82.9%). In addition, compared to the episodic treatment group, the annualized joint bleeding rate was lower in the low-dose prophylactic group (RM: 0.17, 95% CI: 0.06 to 0.43), intermediate-dose prophylactic group (RM of 0.14, 95% CI: 0.07 to 0.27), and high-dose prophylactic group (RM of 0.08, 95% CI: 0.04 to 0.16). Without significant subgroup differences. The certainty of the evidence was very low for all outcomes according to GRADE methodology. The other studies compared different types of clotting factor concentrates (CFCs), assessed pharmacokinetic prophylaxis, or compared different frequencies of medication administration.<\/jats:p><\/jats:sec><jats:sec id=\"sec005\"><jats:title>Conclusions<\/jats:title><jats:p>Our results suggest that prophylactic treatment (at either low, intermediate, or high doses) is superior to episodic treatment for bleeding prevention. In patients with hemophilia A, the bleeding rate seems to have a dose-response effect. However, no study compared different doses of prophylactic treatment, and all results had a very low certainty of the evidence. Thus, future studies are needed to confirm these results and inform decision making.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0262273","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T19:27:59Z","timestamp":1642188479000},"page":"e0262273","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effects of replacement therapies with clotting factors in patients with hemophilia: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"17","author":[{"given":"Carolina J.","family":"Delgado-Flores","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garc\u00eda-Gomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefany","family":"Salvador-Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Montes-Alvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"Herrera-Cunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8758-0463","authenticated-orcid":true,"given":"Alvaro","family":"Taype-Rondan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"pone.0262273.ref001","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"VS Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"pone.0262273.ref002","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries","volume":"171","author":"A Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"pone.0262273.ref003","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/hae.13199","article-title":"A new wave in the evaluation of haemophilic arthropathy","volume":"23","author":"N. Bakeer","year":"2017","journal-title":"Haemophilia"},{"key":"pone.0262273.ref004","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"J. Oldenburg","year":"2015","journal-title":"Blood"},{"key":"pone.0262273.ref005","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(11)61139-2","article-title":"Modern haemophilia care","volume":"379","author":"E Berntorp","year":"2012","journal-title":"Lancet"},{"issue":"Suppl 6","key":"pone.0262273.ref006","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia, 3rd edition","volume":"26","author":"A Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"7","key":"pone.0262273.ref007","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s13312-018-1302-8","article-title":"\u2018Consensus in Diagnosis and Management of Hemophilia\u2019 Committee*, Indian Academy of Pediatrics. Consensus Statement of the Indian Academy of Pediatrics in Diagnosis and Management of Hemophilia","volume":"55","author":"A Sachdeva","year":"2018","journal-title":"Indian Pediatr"},{"key":"pone.0262273.ref008","unstructured":"Ministerio de Salud de Chile (Minsal). Gu\u00eda Cl\u00ednica AUGE: Hemofilia. Santiago-Chile, 2013."},{"key":"pone.0262273.ref009","unstructured":"Fundaci\u00f3n de la Hemofilia. Gu\u00eda para el manejo de la Hemofilia Cong\u00e9nita: consenso para m\u00e9dicos especialistas en Hematolog\u00eda de la Rep\u00fablica de Argentina. Segunda Edici\u00f3n, Buenos Aires, Argentina 2015."},{"issue":"1","key":"pone.0262273.ref010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.15381\/anales.v79i1.14598","article-title":"Gu\u00eda de pr\u00e1ctica cl\u00ednica para el diagn\u00f3stico y tratamiento de hemofilia en el Seguro Social de Salud del Per\u00fa (EsSalud)","volume":"79","author":"Sa\u00fal Mendoza Ordo\u00f1ez","year":"2018","journal-title":"An. Fac. med"},{"key":"pone.0262273.ref011","unstructured":"Instituto de Evaluaci\u00f3n Tecnol\u00f3gica en Salud (IETS). Protocolo cl\u00ednico para el tratamiento con profilaxis de personas con hemofilia A severa sin inhibidores. Ministerio de Salud y Protecci\u00f3n Social. Colombia, Marzo 2015."},{"key":"pone.0262273.ref012","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"A Liberati","year":"2009","journal-title":"BMJ"},{"key":"pone.0262273.ref013","unstructured":"W Keith Hoots, MDAmy D Shapiro, MD. Treatment of bleeding and perioperative management in hemophilia A and B. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA."},{"key":"pone.0262273.ref014","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org."},{"issue":"2","key":"pone.0262273.ref015","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"G Guyatt","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"pone.0262273.ref016","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R Dersimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"7","key":"pone.0262273.ref017","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MPH.0b013e318068b1d6","article-title":"Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy","volume":"29","author":"MR Hacker","year":"2007","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"pone.0262273.ref018","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"MJ Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0262273.ref019","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/jth.12202","article-title":"Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)","volume":"11","author":"MJ Manco-Johnson","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"11","key":"pone.0262273.ref020","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1111\/jth.13811","article-title":"Effect of late prophylaxis in hemophilia on joint status: a randomized trial","volume":"15","author":"MJ Manco-Johnson","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"3","key":"pone.0262273.ref021","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/hae.12838","article-title":"A randomized study of very low-dose factor VIII prophylaxis in severe haemophilia\u2014A success story from a resource limited country","volume":"22","author":"SP Verma","year":"2016","journal-title":"Haemophilia"},{"issue":"3","key":"pone.0262273.ref022","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/jth.12828","article-title":"Prophylaxis vs. on-demand treatment with BAY 81\u20138973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II)","volume":"13","author":"LEOPOLD II Study Investigators","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"pone.0262273.ref023","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/hae.13770","article-title":"Comparison of the efficacy and safety of 12-month low-dose factor VIII tertiary prophylaxis vs on-demand treatment in severe haemophilia A children","volume":"25","author":"NA Chozie","year":"2019","journal-title":"Haemophilia"},{"issue":"4","key":"pone.0262273.ref024","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)","volume":"9","author":"ESPRIT Study Group","year":"2011","journal-title":"J Thromb Haemost"},{"issue":"3","key":"pone.0262273.ref025","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/hae.12344","article-title":"Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects","volume":"20","author":"LA Valentino","year":"2014","journal-title":"Haemophilia"},{"issue":"3","key":"pone.0262273.ref026","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1538-7836.2011.04611.x","article-title":"A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management","volume":"10","author":"LA Valentino","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"5","key":"pone.0262273.ref027","first-page":"913","article-title":"Efficacy and safety of prophylaxis with once-weekly BAY 79\u20134980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study","volume":"108","author":"J Powell","year":"2012","journal-title":"Thromb Haemost"},{"issue":"Suppl 3","key":"pone.0262273.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2516.2006.01253.x","article-title":"The pharmacokinetics of coagulation factors","volume":"12","author":"M Lee","year":"2006","journal-title":"Haemophilia"},{"issue":"6","key":"pone.0262273.ref029","first-page":"745","article-title":"A two-phase linear regression model for biologic half-life data","volume":"115","author":"ML Lee","year":"1990","journal-title":"J Lab Clin Med"},{"issue":"3","key":"pone.0262273.ref030","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/08880018.2017.1313921","article-title":"Efficacy of standard prophylaxis versus on-demand treatment with bayer\u2019s sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A","volume":"34","author":"Y Zhao","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"pone.0262273.ref031","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/hae.12878","article-title":"Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B","volume":"22","author":"K Kavakli","year":"2016","journal-title":"Haemophilia"},{"issue":"no 1","key":"pone.0262273.ref032","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2516.2010.02348.x","article-title":"Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China","volume":"vol. 17","author":"R. Wu","year":"2011","journal-title":"Haemophilia"},{"issue":"10","key":"pone.0262273.ref033","first-page":"1391","article-title":"Breakthrough bleeding in adult patients with severe hemophilia A receiving low- and intermediate-dose FVIII for tertiary prophylaxis: characteristics and influencing factors","volume":"37","author":"SQ Qiu","year":"2017","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"4","key":"pone.0262273.ref034","first-page":"496","article-title":"Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis","volume":"38","author":"JM Zhuang","year":"2018","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"7","key":"pone.0262273.ref035","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/blood-2012-12-470898","article-title":"Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s","volume":"122","author":"K Fischer","year":"2013","journal-title":"Blood"},{"issue":"6","key":"pone.0262273.ref036","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1046\/j.1365-2516.2002.00694.x","article-title":"Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen","volume":"8","author":"K Fischer","year":"2002","journal-title":"Haemophilia"},{"issue":"21","key":"pone.0262273.ref037","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia a","volume":"374","author":"F Peyvandi","year":"2016","journal-title":"N Engl J med"},{"issue":"3","key":"pone.0262273.ref038","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa1208024","article-title":"Factor VIII products and inhibitor development in severe hemophilia A","volume":"368","author":"Group RS","year":"2013","journal-title":"N Engl J med"},{"issue":"5 Suppl","key":"pone.0262273.ref039","first-page":"s126","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"SL Chen","year":"2016","journal-title":"Am J Manag Care"},{"issue":"7","key":"pone.0262273.ref040","first-page":"632","article-title":"Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia","volume":"24","author":"T Thorat","year":"2018","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"pone.0262273.ref041","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0266462303000552","article-title":"Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches","volume":"19","author":"P Royle","year":"2003","journal-title":"International journal of technology assessment in health care"},{"issue":"9","key":"pone.0262273.ref042","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jclinepi.2014.12.017","article-title":"Using data sources beyond PubMed has a modest impact on the results of systematic reviews of therapeutic interventions","volume":"68","author":"CW Halladay","year":"2015","journal-title":"Journal of clinical epidemiology"},{"issue":"2","key":"pone.0262273.ref043","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/rth2.12195","article-title":"Hemophilia trials in the twenty-first century: Defining patient important outcomes","volume":"3","author":"BA Konkle","year":"2019","journal-title":"Res Pract Thromb Haemost"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262273","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T21:16:28Z","timestamp":1700082988000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262273"}},"subtitle":[],"editor":[{"given":"Wolfgang","family":"Miesbach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262273","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]}}}